marketing wars over the new sleeping pills

September 2005

You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.

Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.

Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote